Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$172.19 - $263.05
Previous CloseN/A
Volume178.41K
Average Volume (3M)928.83K
Market Cap
$32.88B
Enterprise Value$34.05B
Total Cash (Recent Filing)$520.94M
Total Debt (Recent Filing)$143.70M
Price to Earnings (P/E)26.4
Beta1.20
Next Earnings
Apr 24, 2025EPS Estimate
2.38Last Dividend Ex-Date
Feb 13, 2025Dividend Yield0.92%
Share Statistics
EPS (TTM)8.46
Shares Outstanding146,866,910
10 Day Avg. Volume777,581
30 Day Avg. Volume928,831
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)N/A
Price to Sales (P/S)6.55
Price to Cash Flow (P/CF)26.10
P/FCF Ratio26.10
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.82
Enterprise Value/Ebitda20.56
Forecast
1Y Price Target
$272.11Price Target Upside22.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Resmed News
---
Bulls Say, Bears Say
Bulls Say
Device GrowthUS Device growth at 12% outpaces the CPAP market growth rate of 5-7%, indicating greater new patient engagement at the PCP level.
Financial PerformanceRMD's gross margin was up 230 bps Y/Y and its operating margin was up 260 bps Y/Y due to pricing, manufacturing efficiencies, and lower component costs.
Market PositionThe company plays in very large and historically underserved markets and enjoys a majority share position.
Bears Say
Device DemandAn estimated 18% of CPAP patients using a GLP-1 drug may be cured of their OSA, reducing the need for CPAP devices.
Market ImpactOver 50% of Sleep Specialists believe GLP-1s will slow the growth trajectory of the CPAP market.
Regulatory RiskThe risk posed by the recent FDA approval of the first GLP-1 drug for obstructive sleep apnea (OSA) and Medicare's plans to cover the drug for OSA.
---
Ownership Overview
0.52% Insiders
16.89% Mutual Funds
9.40% Other Institutional Investors
48.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $172.19 and its highest was $263.05 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $32.88B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Apr 24, 2025 which is in 21 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Jan 30, 2025. The company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.316 by $0.114.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $2.066 which represents an annual dividend yield of 0.92%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.38.
How many shares outstanding does Resmed have?
Resmed has 146,866,910 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.43 in its last earnings report, beating expectations of $2.316. Following the earnings report the stock price went down -8.332%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
---
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$272.11 (22.02% Upside)
$272.11 (22.02% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 88%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $499.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.05%
12-Months-Change
Fundamentals
Return on Equity
25.65%
Trailing 12-Months
Asset Growth
3.42%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
---
RMD Company Deck
---
RMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant growth in revenue, device sales, and earnings per share. The company highlighted successful product innovations and strategic collaborations. Despite some currency-related revenue impacts and potential tariff concerns, the overall sentiment remains positive with a focus on sustained growth and innovation.Read More>---
RMD Revenue Breakdown
87.53% Sleep and Respiratory Care
12.47% Software as a Service
---
RMD Stock 12 Month Forecast
Average Price Target
$272.11
▲(22.02% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Koninklijke Philips
―
Medtronic
―
Thermo Fisher
―
Best Analysts Covering RMD
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+10.10%
reiterated a buy rating 2 months ago
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +10.10% per trade.
---